HDHerman T. Den Dekker

Herman T. Den Dekker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Herman T. Den Dekker has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Liesbeth Duijts

    Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Neonatology and Pediatric Intensive Care, Division of Neonatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

    3 shared publications
  • Ahmed Edris

    Nuffield Department of Population Health, University of Oxford, Oxford, UK

    2 shared publications
  • Erik Melén

    Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    2 shared publications
  • Johan C. de Jongste

    Division of Respiratory Medicine, Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

    2 shared publications
  • Lies Lahousse

    Department of Bioanalysis, Faculty of Pharmaceutical Sciences Ghent University Ghent Belgium

    2 shared publications
  • Marielle W. Pijnenburg

    Division of Respiratory Medicine and Allergology, Department of Pediatrics University Medical Center Rotterdam, Erasmus MC—Sophia Children's Hospital Rotterdam the Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Update on biologic and small molecules treatments in pediatric allergic diseases

    by Herman T. Den Dekker, Amandine Divaret Chauveau, Benoit Sterling, Stéphanie Coopman, R. Sharon Chinthrajah, Stéphanie Lejeune, Dorothea Holter, Thomas Eiwegger, Stéphanie Mallet, Mariëlle W. Pijnenburg, et al.

    Biologics have revolutionized the treatment of severe allergic diseases in children that cannot be controlled by conventional treatments. These diseases are commonly driven by dysregulation of immune response, often driven by Type 2 pathways. By targeting them, biologics have the potential for treating one or more allergic diseases. Thus, a “treat to target” strategy is now prioritized, allowing treatment of allergic diseases in a personalized approach. The pioneer anti‐IgE monoclonal antibody, omalizumab, was initially indicated for the treatment of moderate to severe allergic asthma and is now indicated for chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and food allergy (FA), highlighting the ability of biologics to target multiple allergic diseases. Other biologics have been developed in asthma and other allergic diseases, including mepolizumab (anti‐IL5), benralizumab (anti‐IL5 receptor), dupilumab (anti–IL‐4 receptor α), and more recently tezepelumab (anti‐TSLP). Clinical trials in children and/or teenagers have demonstrated their efficacy and safety, confirmed by real‐life studies, in asthma, atopic dermatitis (AD), CSU, and more recently in eosinophilic esophagitis (EoE) and FA. Beyond biologics, small molecules such as Janus kinase inhibitors target other key pathways and have already been approved in AD, with ongoing clinical trials in other allergic diseases. In the pediatric specific context, these treatments raise questions, particularly regarding the choice of biologics and the goals. In the long term, the sustained efficacy, safety and impact on the natural history of allergic diseases need to be further studied. The aim of this review is to discuss the most recent data in the use of biologics and small molecules in pediatric allergic diseases and to highlight the remaining gaps in knowledge.

  • Open Access

    Cover Image

    by Ahmed Edris, Herman T. Den Dekker, Erik Melén, Lies Lahousse

  • Epigenome‐wide association studies in asthma: A systematic review

    by Ahmed Edris, Herman T. Den Dekker, Erik Melén, Lies Lahousse

    Objective: Asthma is a common chronic respiratory airway disease influenced by environmental factors and possibly their interaction with the human genome causing epigenetic changes. Epigenome‐wide association studies (EWAS) have mainly investigated DNA methylation and its association with disease or traits, exposure factors or gene expression. This systematic review aimed to identify all EWAS assessing differentially methylated sites associated with asthma in humans.Design: Structured systematic literature search following PRISMA guidelines, Newcastle‐Ottawa Scale (NOS) for cohort studies was used for bias assessment.Data Sources: We searched PubMed and Embase databases from 2005 to 2019.Eligibility Criteria: Epigenome‐wide association studies testing association between differential methylation and asthma in humans.Results: Overall, we identified 16 EWAS studies complying with our search criteria. Twelve studies were conducted on children, and 10 were conducted on sample sizes SMAD3, SERPINC1, PROK1, IL13, RUNX3 and TIGIT. Forty‐one CpGs were replicated at least once in blood samples, and 28 CpGs were replicated in nasal samples.Conclusion: Although many differentially methylated CpGs in genes known to be involved in asthma have been identified in EWAS to date, we conclude that further studies of larger sample sizes and analyses of differential methylation between different phenotypes are needed in order to comprehensively evaluate the role of epigenetic factors in the pathophysiology and heterogeneity of asthma, and the potential clinical utility to predict or classify patients with asthma.


  • Early childhood growth patterns and lung function and asthma at 10 years

    by Maribel Casas Sanahuja, Herman T. Den Dekker, Claudia J. Kruithof, Irwin K. Reiss, Martine Vrijheid, Jordi Sunyer, Johan C. De Jongste, Vincent W.V. Jaddoe, Liesbeth Duijts

    Greater infant weight gain is associated with lower lung function and increased risk of childhood asthma. Detailed individual childhood growth patterns might be better predictors of childhood respiratory morbidity than the difference in two measurements of weight and height. We assessed the associations of early childhood growth patterns with lung function and asthma at the age of 10 years and whether child’s current body mass index (BMI) influenced any association. In 4,435 children from the Generation R birth cohort study in Rotterdam, the Netherlands, we derived peak height and weight growth velocity, body mass index at adiposity peak, and age at adiposity peak from longitudinally measured growth data in the first 3 years of life. At 10 years, spirometry was performed including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and FEV1/FVC. Current asthma was assessed by questionnaires. Per standard deviation score, greater peak weight velocity was associated with higher FVC (z-score 0.03 [95% CI, 0.02 to 0.05]) but lower FEV1/FVC (-0.05 [95% CI, -0.07 to -0.04]). Greater body mass index at adiposity peak was associated with higher FVC (0.14 [0.10 to 0.18]) and FEV1 (0.06 [0.02 to 0.10]) but lower FEV1/FVC (-0.15 [-0.19 to -0.11]). Child’s current BMI partly explained the associations of PWV and FEV1/FVC and of BMIAP with FVC and FEV1/FVC. Peak height velocity and age at adiposity peak were not consistently associated with impaired lung function or asthma. Peak weight velocity and body mass index at adiposity peak were associated with lower lung function measures at age 10 years, not asthma, independently of child’s current weight status.


  • Maternal hemoglobin and hematocrit levels during pregnancy and childhood lung function and asthma. The Generation R Study

    by Sabrina M. C. B. Pereira de Jesus, Herman T. Den Dekker, Johan C. de Jongste, Irwin K. Reiss, Eric A. Steegers, Vincent W. V. Jaddoe, Liesbeth Duijts

    Objective: To examine the associations of maternal hemoglobin and hematocrit levels during pregnancy with childhood lung function and asthma, and whether adverse pregnancy outcomes and atopic predisposition modify the associations.Methods: In a population‐based prospective cohort study among 3672 subjects, we measured maternal hemoglobin and hematocrit levels in early pregnancy, and lung function by spirometry and current asthma by questionnaire at age 10 years.Results: Higher maternal hematocrit levels, both continuously and categorized into clinical cut‐offs, were associated with lower forced expiratory flow at 75% of forced vital capacity (FEF75) in children (Z‐score (95%CI): −0.04 (−0.07, −0.01), per increase of 1 SDS in hematocrit level; Z‐score (95%CI) difference: −0.11 (−0.20, −0.03) compared with normal hematocrit levels, respectively), taking lifestyle and socio‐economic factors into account. Adverse pregnancy outcomes and atopic predisposition did not modify the results. No associations of maternal hemoglobin and hematocrit with current asthma were observed.Conclusion: Higher maternal hematocrit levels during pregnancy are associated with lower childhood lung function but not with risk of asthma. Adverse pregnancy outcomes and atopic predisposition do not modify these associations. Underlying mechanisms need to be further studied.


  • Maternal folic acid use during pregnancy, methylenetetrahydrofolate reductase gene polymorphism, and child's lung function and asthma

    by H. T. Den Dekker, V. W.V. Jaddoe, I. K. Reiss, J. C. de Jongste, L. Duijts

    Summary: Background: Folic acid supplement use during pregnancy might affect childhood respiratory health, potentially mediated by methylenetetrahydrofolate reductase polymorphism C677T (MTHFR‐C677T) carriership.Objectives: We examined the associations of maternal folic acid supplement use and folate, vitamin B12 and homocysteine concentrations during pregnancy with childhood lung function and asthma.Methods: This study was embedded in a population‐based prospective cohort study among 5653 children. Folic acid supplement use was assessed by questionnaires. Folate, vitamin B12 and homocysteine plasma concentrations were measured in early pregnancy and at birth. At age 10 years, forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, forced expiratory flow between 25% and 75% (FEF25‐75), at 75% of FVC (FEF75), and asthma were examined.Results: Maternal folic acid supplement use during pregnancy was associated with higher childhood FEV1 and FVC and with a lower FEV1/FVC, compared with no folic acid supplement use. Among mothers carrying MTHFR‐C677T variants, preconceptional start of folic acid supplement use was associated with lower FEV1/FVC (−0.17 [−0.32, −0.02]) and FEF25‐75 (−0.24 [−0.40, −0.07]). Among children carrying MTHFR‐C677T wild‐type, a higher vitamin B12 level at birth was associated with a lower FEV1 (−0.07 [−0.12, −0.01]) and FVC (−0.09 [−0.15, −0.04]). Folate and homocysteine concentrations were not consistently associated with lower childhood lung function or asthma.Conclusions: Preconceptional start of maternal folic acid supplement use and higher vitamin B12 concentrations at birth might adversely affect childhood lung function depending on MTHFR‐C677T carriership. The clinical implications need to be evaluated.


  • Structural and functional ventilatory impairment in infants with severe bronchopulmonary dysplasia

    by Esther van Mastrigt, Ellaha Kakar, Pierluigi Ciet, Herman T. Den Dekker, Koen F. Joosten, Patricia Kalkman, Renate Swarte, André A. Kroon, Harm A. W. M. Tiddens, Johan C. de Jongste, et al.

    Bronchopulmonary dysplasia (BPD) is the most frequent serious complication in preterm infants. We aimed to describe lung structure and ventilatory function of preterm infants with severe BPD and explored the association between early postnatal growth and these outcomes. We included preterm infants born ≤32 weeks gestational age (GA) with severe BPD. Lung structure was assessed on chest CT with the PRAGMA-BPD scoring system and ventilatory function by polysomnography (PSG) at 6 months corrected age. Postnatal growth was assessed by weight measured at birth, and at 2 and 6 months corrected age. We included 49 infants (median [IQR] GA of 25.7 [24.6-26.3] weeks and mean [SD] birth weight of 760 [210] g). A 95.5% of the chest CT scans showed architectural distortion of the lung, and an oxygen desaturation index (ODI) >5 was found in 74% of the infants. An increase in GA of 1 week was associated with higher total and normal lung volume (β coefficient [95% CI]: 1.86 [0.15, 3.57] and 2.03 [0.41, 3.65]), less hypoattenuation (−4.3 [−7.70, −0.90]%) and lower ODI (−36.7 [−64.2, −9.10]%). Higher weight at 6 months was independently associated with higher total and normal lung volume, and with less severe desaturations. Increased weight gain between 2 and 6 months of corrected age was associated with less severe desaturations during sleep (β coefficient [95% CI]: 2.09 [0.49, 3.70]). Most preterm infants with severe BPD have structural lung abnormalities and impaired ventilatory function early in life, partly explained by birth characteristics and infant growth.